Research Library

Using charts, figures and graphs of this survey data originally created by former career intelligence analyst Brian C. Bennett and updated by the Drug Policy Program, this issue brief offers an overview of drug use trends in America over the last four decades. The brief is part of a larger online project chronicling the pattern of the use and abuse of individual drugs over (in most cases) more than 40 years.

The percentage of Hispanics in Texas without health insurance has dropped by 30 percent since the Affordable Care Act (ACA) went into effect, but almost one-third of Hispanic Texans ages 18 to 64 remain uninsured.

The percentage of Texans without health insurance has dropped by 30 percent since the Affordable Care Act (ACA) went into effect, cutting the state’s uninsured rate below 1999 levels.

This study assesses the attitudes of women in Jordanian maternity clinics with regard to CB banking and transplantation.

Former Secretary of State James A. Baker, III, testified on May 12, 2016, before the Senate Committee on Foreign Relations on America's role in the world.

This journal article examines the risks patients face in seeking experimental stem cell-based interventions from clinics outside the United States. The authors advocate for new public policies that encourage patients to remain in clinical trials in the U.S.

Constantino Urcuyo, nonresident fellow for the Latin America Initiative, testified at a House Foreign Affairs subcommittee hearing on Russia's engagement in Latin America.

While the Food and Drug Administration currently regulates storage and use of cord blood (CB) in the United States, other state and federal guidelines on CB education, awareness and ethical considerations remain variable, and no mandatory international guidelines exist. To help organize and coordinate efforts across the United States and other nations, policymakers should implement regulations for high quality standards for both private and public CB banks.

Regenerative medicine and stem cell research are exciting new fields. But as the fields progress toward clinical therapies, controversies emerge. Hype surrounding stem cell research has caused an increase in their use in interventions that are not clinically proven. Furthermore, the regulatory agencies have a lot of difficulty dealing with cell therapies, which are distinctly different from drugs and medical devices they more commonly approve. To move the field forward, advocates, regulators and scientists need to come together to find new options for stem cell research oversight that protects both the patients and the research field.

William Martin, director of the Drug Policy Program, and Katharine A. Neill, Alfred C. Glassell, III Postdoctoral Fellow in Drug Policy, testify about the likelihood of marijuana being used as a gateway to harder drugs and the effects of decriminalization on teen use rates before the Texas House Criminal Jurisprudence Committee.